BR112012007509A2 - derivados pirazóis que modulam estearoil-coa dessaturase - Google Patents

derivados pirazóis que modulam estearoil-coa dessaturase

Info

Publication number
BR112012007509A2
BR112012007509A2 BR112012007509A BR112012007509A BR112012007509A2 BR 112012007509 A2 BR112012007509 A2 BR 112012007509A2 BR 112012007509 A BR112012007509 A BR 112012007509A BR 112012007509 A BR112012007509 A BR 112012007509A BR 112012007509 A2 BR112012007509 A2 BR 112012007509A2
Authority
BR
Brazil
Prior art keywords
modulate
pyrazole derivatives
coa desaturase
derivatives
stearoyl coa
Prior art date
Application number
BR112012007509A
Other languages
English (en)
Inventor
Jianmin Fu
Natalia Pokrovskaia
Natalie Dales
Qi Jia
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43066810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012007509(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of BR112012007509A2 publication Critical patent/BR112012007509A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados pirazóis que modulam estearoll-coa dessaturase - a presente invenção refere-se a derivados heterocíclicos que modulam a atividade de estearoil-coa dessaturasse. métodos de utilização de tais derivados para modular a atividade estearoil-coa dessaturasse e composições farmacêuticas compreendendo tais derivados são também abrangidos.
BR112012007509A 2009-10-01 2010-10-01 derivados pirazóis que modulam estearoil-coa dessaturase BR112012007509A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24763409P 2009-10-01 2009-10-01
PCT/EP2010/064672 WO2011039358A1 (en) 2009-10-01 2010-10-01 Pyrazole derivatives which modulate stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
BR112012007509A2 true BR112012007509A2 (pt) 2016-11-22

Family

ID=43066810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007509A BR112012007509A2 (pt) 2009-10-01 2010-10-01 derivados pirazóis que modulam estearoil-coa dessaturase

Country Status (22)

Country Link
US (1) US20130011361A1 (pt)
EP (1) EP2483264A1 (pt)
JP (1) JP2013506638A (pt)
KR (1) KR20120080226A (pt)
CN (1) CN102574841A (pt)
AU (1) AU2010302577A1 (pt)
BR (1) BR112012007509A2 (pt)
CA (1) CA2776294A1 (pt)
CL (1) CL2012000797A1 (pt)
CO (1) CO6761294A2 (pt)
CR (1) CR20120134A (pt)
EA (1) EA201200545A1 (pt)
EC (1) ECSP12011837A (pt)
IL (1) IL218294A0 (pt)
IN (1) IN2012DN01913A (pt)
MA (1) MA33693B1 (pt)
MX (1) MX2012003938A (pt)
PE (1) PE20121439A1 (pt)
SG (1) SG178869A1 (pt)
TN (1) TN2012000085A1 (pt)
WO (1) WO2011039358A1 (pt)
ZA (1) ZA201201390B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6254087B2 (ja) 2011-10-15 2017-12-27 ジェネンテック， インコーポレイテッド 癌を治療するためのｓｃｄ１アンタゴニスト
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
IL304017A (en) 2017-01-06 2023-08-01 Yumanity Therapeutics Inc Methods for treating neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
MA52092A (fr) * 2018-03-23 2021-01-27 Yumanity Therapeutics Inc Composés et leurs utilisations
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171465B1 (en) 1999-03-29 2004-08-04 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
ES2307534T3 (es) 1999-09-28 2008-12-01 Bayer Corporation Agonistas de receptores 3 (r3) del peptido activador de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologicos.
AU4722801A (en) 2000-02-24 2001-09-03 Xenon Genetics Inc Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
ATE402262T1 (de) 2000-09-26 2008-08-15 Xenon Pharmaceuticals Inc Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
AR051092A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
US7919496B2 (en) * 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
CL2007002348A1 (es) * 2006-08-15 2008-08-08 Novartis Ag Xenon Pharmaceutic Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne.
JP2010501567A (ja) * 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
BRPI0718509A2 (pt) * 2006-09-22 2015-09-29 Novartis Ag compostos orgânicos heterocíclicos
US8068738B2 (en) * 2007-02-21 2011-11-29 Tte Technology, Inc. System and method for decoding infra-red (IR) signals
BRPI0907826A2 (pt) * 2008-02-20 2019-12-10 Novartis Ag inibidores heterocíclicos de estearoil-coa desaturase

Also Published As

Publication number Publication date
US20130011361A1 (en) 2013-01-10
MX2012003938A (es) 2012-08-03
MA33693B1 (fr) 2012-10-01
IN2012DN01913A (pt) 2015-07-24
IL218294A0 (en) 2012-04-30
JP2013506638A (ja) 2013-02-28
CO6761294A2 (es) 2013-09-30
CL2012000797A1 (es) 2013-08-09
ECSP12011837A (es) 2012-06-29
EA201200545A1 (ru) 2012-12-28
CN102574841A (zh) 2012-07-11
AU2010302577A1 (en) 2012-03-15
CA2776294A1 (en) 2011-04-07
SG178869A1 (en) 2012-04-27
PE20121439A1 (es) 2012-11-06
ZA201201390B (en) 2012-10-31
TN2012000085A1 (en) 2013-09-19
CR20120134A (es) 2012-05-17
WO2011039358A1 (en) 2011-04-07
EP2483264A1 (en) 2012-08-08
KR20120080226A (ko) 2012-07-16

Similar Documents

Publication Publication Date Title
BRPI0907826A2 (pt) inibidores heterocíclicos de estearoil-coa desaturase
CU23914B1 (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA
SMT201700036B (it) Composti e composizioni come inibitori di protein chinasi
PH12014502613A1 (en) Synthesis of heterocyclic compound
BR112012007509A2 (pt) derivados pirazóis que modulam estearoil-coa dessaturase
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
MX2009003080A (es) Compuestos organicos heterociclicos.
BRPI1014281A2 (pt) azetidinil diamidas como inibidores da monoacilglicerol lipase
MA33976B1 (fr) Spiroindolinone pyrrolidines
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
NO20084334L (no) Farmasoytiske sammensetninger
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
ECSP11011340A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
GEP20156241B (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000598A1 (en) Organic compounds
UY34231A (es) Eliminación de inhibidores de la fermentación microbiana de hidrolizados celulósicos u otras composiciones que contienen inhibidores
CU20120052A7 (es) Derivados de pirazol que modulan estearoil-coa-desaturasa
DOP2009000099A (es) Compuestos y composiciones como inhibidores de proteina cinasa
AR078297A1 (es) Composicion de liposoma

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/247,634 REIVINDICADA NO PCT/EP2010/064672, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE OS DEPOSITANTES CONSTANTES DA PETICAO DE REQUERIMENTO DO PEDIDO PCT SEREM DISTINTOS DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO DE TODOS OS INVENTORES DENTRO DO PRAZO DE 60 DIAS A CONTAR DA DATA DA ENTRADA DA FASE NACIONAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]